Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer. ADMET DMPK [Internet]. 2016 Oct. 1 [cited 2026 Jul. 31];4(3):186-211. Available from: https://pub.iapchem.org/ojs/index.php/admet/article/view/337